HK1255136A1 - Xia凝血因子的抗體及其用途 - Google Patents

Xia凝血因子的抗體及其用途

Info

Publication number
HK1255136A1
HK1255136A1 HK18114221.2A HK18114221A HK1255136A1 HK 1255136 A1 HK1255136 A1 HK 1255136A1 HK 18114221 A HK18114221 A HK 18114221A HK 1255136 A1 HK1255136 A1 HK 1255136A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
coagulation factor
factor xia
xia
coagulation
Prior art date
Application number
HK18114221.2A
Other languages
English (en)
Inventor
Thomas Mikita
Lauren K Ely
Huilan Gao
Yun Kim
Isaac J Rondon
Tovo David
Shaun R Coughlin
Original Assignee
Univ California
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Pfizer filed Critical Univ California
Publication of HK1255136A1 publication Critical patent/HK1255136A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18114221.2A 2015-07-23 2018-11-07 Xia凝血因子的抗體及其用途 HK1255136A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562196037P 2015-07-23 2015-07-23
PCT/US2016/043703 WO2017015619A1 (en) 2015-07-23 2016-07-22 Antibodies to coagulation factor xia and uses thereof

Publications (1)

Publication Number Publication Date
HK1255136A1 true HK1255136A1 (zh) 2019-08-09

Family

ID=57835253

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114221.2A HK1255136A1 (zh) 2015-07-23 2018-11-07 Xia凝血因子的抗體及其用途

Country Status (5)

Country Link
US (2) US11066481B2 (zh)
EP (1) EP3325010B1 (zh)
CA (1) CA3025896A1 (zh)
HK (1) HK1255136A1 (zh)
WO (1) WO2017015619A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017127468A1 (en) 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TW201802121A (zh) * 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CA3025869A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
PE20191319A1 (es) 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
JP2021503891A (ja) * 2017-11-22 2021-02-15 ノバルティス アーゲー 抗第ＸＩ／ＸＩａ因子抗体に対する反転結合剤およびそれらの使用
WO2020089380A1 (en) 2018-10-31 2020-05-07 Bayer Aktiengesellschaft REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIa ANTIBODIES
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CA3184718A1 (en) * 2020-07-02 2022-01-06 Lei Wang Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2023092062A1 (en) * 2021-11-18 2023-05-25 Anthos Therapeutics, Inc. Dosing regimens of factor xi/xia antibodies

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2086417C (en) 1990-06-29 1999-07-06 Biosource Technologies, Inc. Melanin production by transformed organisms
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
ES2181673T3 (es) 1991-05-01 2003-03-01 Jackson H M Found Military Med Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
DK0695169T3 (da) 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2166118C (en) 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435224D1 (de) 1993-09-15 2009-09-10 Novartis Vaccines & Diagnostic Rekombinante Alphavirus-Vektoren
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
RU2160093C2 (ru) 1993-11-16 2000-12-10 Скайефарма Инк. Везикулы с регулируемым высвобождением активных ингредиентов
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DK2070939T3 (da) 2001-05-25 2014-06-23 Univ Duke Modulatorer af farmakologiske midler
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP3502133A1 (en) 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1575517B1 (en) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US7217794B2 (en) 2003-04-02 2007-05-15 Daiamed, Inc. Compounds and methods for treatment of thrombosis
US20050181978A1 (en) 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US7314622B2 (en) 2005-04-15 2008-01-01 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
PT3002298T (pt) 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
DK2796469T3 (da) 2008-09-17 2019-08-12 Xencor Inc Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
US8388959B2 (en) * 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EP2611901B1 (en) 2010-08-30 2016-05-11 Novozymes A/S Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same
CN104684932B (zh) * 2012-05-10 2019-03-12 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途
WO2014075045A1 (en) 2012-11-12 2014-05-15 Virginia Commonwealth University ALLOSTERIC MODULATORS OF FACTOR XIa AS ANTICOAGULANT AGENTS
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3324992A4 (en) 2015-07-23 2018-12-26 The Regents of The University of California REVERSAL AGENTS FOR FXIa INHIBITORS

Also Published As

Publication number Publication date
EP3325010A4 (en) 2019-03-27
CA3025896A1 (en) 2017-01-26
EP3325010B1 (en) 2023-06-21
EP3325010A1 (en) 2018-05-30
US11066481B2 (en) 2021-07-20
US20210403600A1 (en) 2021-12-30
US20200095334A1 (en) 2020-03-26
WO2017015619A1 (en) 2017-01-26
WO2017015619A8 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
HK1255136A1 (zh) Xia凝血因子的抗體及其用途
IL283321A (en) Antibodies against muc16 and their uses
IL285375A (en) Antibodies that bind to il-8 and their uses
HK1254861A1 (zh) 抗lag3抗體及其用途
HK1255067A1 (zh) 抗c10orf54抗體及其用途
HK1250238A1 (zh) 抗angptl8抗體及其用途
HK1243440A1 (zh) 抗白細胞介素-33抗體及其用途
HK1256381A1 (zh) 抗pacap抗體及其用途
IL247407B (en) Antibodies against egfrviii and their uses
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL251001A0 (en) Anti-il-25 antibodies and their uses
PL3292154T3 (pl) Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania
HK1254240A1 (zh) 抗羥腐胺賴氨酸抗體及其用途
SG11201705748SA (en) Anti-glycoprotein antibodies and uses thereof